Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Successful and safe treatment of hemangioma with oral propranolol in a single institution

  • Chung, Sun-Hee (Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Park, Dong-Hyuk (Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Jung, Hye-Lim (Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Shim, Jae-Won (Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Kim, Deok-Soo (Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Shim, Jung-Yeon (Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Park, Moon-Soo (Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Koo, Hong-Hoe (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2011.08.01
  • Accepted : 2012.11.28
  • Published : 2012.05.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Dramatic improvement of hemangioma to propranolol has been recently reported; however, details on dose and duration of treatment, potential risks, and monitoring have not been determined. The objective of this study is to describe and analyze the use of propranolol as a first-line treatment or as a single therapy in management of complicated hemangioma. Methods: A retrospective chart review of eight patients diagnosed with hemangioma and treated with propranolol in Kangbuk Samsung Hospital from February 2010 to April 2011 was performed. Results: Eight patients with hemangioma with functional impairment, cosmetic disfigurement, or rapid growth were treated with propranolol. Five patients had solitary facial hemangioma. The mean age of symptoms at onset was 5 weeks. The median age for starting propranolol treatment was 5.5 months. Propranolol at 2 mg/kg/day was finally administered in divided doses with a gradual increase. Significant regression was observed in seven patients, and shrinkage in size, softening in consistency, and decrease in redness were evident within 4 weeks. Among them, six patients were still taking propranolol, and one patient had stopped after 12 months. Other one patient did not show significant improvement with satisfactory result after 3 months of propranolol use. Treatment with propranolol was well tolerated and had few side effects. No rebound growth was observed in any of the patients. Conclusion: We observed that use of propranolol was very effective in treatment of hemangioma without obvious adverse effects or relapse.

Keywords

References

  1. Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg 1982;69:412-22. https://doi.org/10.1097/00006534-198203000-00002
  2. Chiller KG, Passaro D, Frieden IJ. Hemangiomas of infancy: clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. Arch Dermatol 2002;138:1567-76. https://doi.org/10.1001/archderm.138.12.1567
  3. Hemangioma Investigator Group, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 2007;150:291-4. https://doi.org/10.1016/j.jpeds.2006.12.003
  4. Chang LC, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics 2008;122:360-7. https://doi.org/10.1542/peds.2007-2767
  5. Pandey A, Gangopadhyay AN, Upadhyay VD. Evaluation and management of infantile hemangioma: an overview. Ostomy Wound Manage 2008;54:16-8, 20, 22-6, 28-9.
  6. Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358:2649-51. https://doi.org/10.1056/NEJMc0708819
  7. Lee EK, Choung HK, Kim NJ, Lee MJ, Kwon BS, Khwarg SI. A case of periorbital infantile capillary hemangioma treated with propranolol. J Korean Ophthalmol Soc 2010;51:1513-9. https://doi.org/10.3341/jkos.2010.51.11.1513
  8. Maguiness SM, Frieden IJ. Current management of infantile hemangiomas. Semin Cutan Med Surg 2010;29:106-14. https://doi.org/10.1016/j.sder.2010.03.009
  9. Cohen SR, Wang CI. Steroid treatment of hemangioma of the head and neck in children. Ann Otol Rhinol Laryngol 1972;81:584-90. https://doi.org/10.1177/000348947208100419
  10. Rossler J, Wehl G, Niemeyer CM. Evaluating systemic prednisone therapy for proliferating haemangioma in infancy. Eur J Pediatr 2008;167:813-5. https://doi.org/10.1007/s00431-007-0561-5
  11. Lomenick JP, Reifschneider KL, Lucky AW, Adams D, Azizkhan RG, Woo JG, et al. Prevalence of adrenal insufficiency following systemic glucocorticoid therapy in infants with hemangiomas. Arch Dermatol 2009;145:262-6. https://doi.org/10.1001/archdermatol.2008.572
  12. Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 2010;163:269-74. https://doi.org/10.1111/j.1365-2133.2010.09848.x
  13. Holmes WJ, Mishra A, Gorst C, Liew SH. Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. J Plast Reconstr Aesthet Surg 2011;64:445-51. https://doi.org/10.1016/j.bjps.2010.07.009
  14. Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol 2009;26:610-4. https://doi.org/10.1111/j.1525-1470.2009.00975.x
  15. Tan ST, Itinteang T, Leadbitter P. Low-dose propranolol for infantile haemangioma. J Plast Reconstr Aesthet Surg 2011;64:292-9. https://doi.org/10.1016/j.bjps.2010.06.010
  16. Rosbe KW, Suh KY, Meyer AK, Maguiness SM, Frieden IJ. Propranolol in the management of airway infantile hemangiomas. Arch Otolaryngol Head Neck Surg 2010;136:658-65. https://doi.org/10.1001/archoto.2010.92
  17. Chik KK, Luk CK, Chan HB, Tan HY. Use of propranolol in infantile haemangioma among Chinese children. Hong Kong Med J 2010;16:341-6.
  18. Frieden IJ, Drolet BA. Propranolol for infantile hemangiomas: promise, peril, pathogenesis. Pediatr Dermatol 2009;26:642-4. https://doi.org/10.1111/j.1525-1470.2009.00977.x
  19. Leboulanger N, Fayoux P, Teissier N, Cox A, Van Den Abbeele T, Carrabin L, et al. Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: a preliminary retrospective study of French experience. Int J Pediatr Otorhinolaryngol 2010;74:1254-7. https://doi.org/10.1016/j.ijporl.2010.07.025

Cited by

  1. Update September 2012 vol.10, pp.3, 2012, https://doi.org/10.1089/lrb.2012.1035
  2. Propranolol as Diagnostic Tool for Infantile Hemangiomas vol.24, pp.6, 2012, https://doi.org/10.1097/scs.0b013e3182a24832
  3. Recent advances in pediatric hemato-oncologic disease vol.59, pp.9, 2016, https://doi.org/10.5124/jkma.2016.59.9.676
  4. Update on recent research into infantile hemangioma vol.59, pp.9, 2012, https://doi.org/10.5124/jkma.2016.59.9.698
  5. Infantile Periocular Hemangioma vol.12, pp.2, 2012, https://doi.org/10.4103/jovr.jovr_66_17
  6. Serum cytokine profiles in infants with infantile hemangiomas on oral propranolol treatment: VEGF and bFGF, potential biomarkers predicting clinical outcomes vol.88, pp.5, 2020, https://doi.org/10.1038/s41390-020-0862-1
  7. Update on infantile hemangioma vol.64, pp.11, 2021, https://doi.org/10.3345/cep.2020.02061